Drugs Made In America Acquisition II Corp. Ordinary Shares (DMII) — Financial Flexibility Index
Drugs Made In America Acquisition II Corp. Ordinary Shares (DMII) has a Financial Flexibility Index of -0.02x as of December 2025. Free cash flow of $-314.86K (operating CF $-314.86K minus capex $0.00) represents 0% of total liabilities ($17.80 Million). Also explore net asset growth rate of Drugs Made In America Acquisition II Cor to track the company's year-over-year net asset growth rate.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Drugs Made In America Acquisition II Corp. Ordinary Shares Financial Flexibility Index (2024–2025)
Historical Financial Flexibility Index trend for Drugs Made In America Acquisition II Corp. Ordinary Shares across 2 annual periods. See how leveraged is Drugs Made In America Acquisition II Cor's balance sheet to measure how much of total assets are equity-financed.
Annual Financial Flexibility Index for Drugs Made In America Acquisition II Corp. Ordinary Shares (2024–2025)
Year-by-year free cash flow to debt coverage for Drugs Made In America Acquisition II Corp. Ordinary Shares. For the full company profile including market capitalisation, see Drugs Made In America Acquisition II Cor stock valuation.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -0.06x | $-1.02 Million | $-1.02 Million | $17.80 Million | ▲ +92.5% |
| 2024 | -0.76x | $-194.30K | $-194.30K | $254.78K | — |